<DOC>
	<DOCNO>NCT00926731</DOCNO>
	<brief_summary>A study ass safety tolerability AZD1152 combination low dose cytosine arabinoside ( LDAC ) patient acute myeloid leukaemia ( AML ) . The first three patient complete 28 day cycle cohort , second three patient start treatment .</brief_summary>
	<brief_title>Study Assess Safety Tolerability AZD1152 Combination With Low Dose Cytosine Arabinoside ( LDAC )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Newly diagnose patient . Provision write informed consent . De Novo ( primary ) Secondary AML . Not eligible intensive induction chemotherapy medical , social psychological reason . Patients AML FAB M3 classification Acute Promyelocytic Leukaemia ( APL ) . Patients blast crisis chronic myeloid leukaemia . Persistent , chronic , clinically significant toxicity prior anti cancer therapy great CTCAE Grade 1 ( except alopecia ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Acute Myeloid Leukaemia ( AML )</keyword>
</DOC>